- Home
- RAPT vs LEO Comparison
RAPT vs LEO Comparison
Compare RAPT & LEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RAPT | LEO |
|---|---|---|
| Founded | 2015 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.4M | 402.8M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | RAPT | LEO |
|---|---|---|
| Price | $35.10 | $6.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $57.00 | N/A |
| AVG Volume (30 Days) | ★ 433.7K | 200.2K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.01% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $152.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.67 | $4.98 |
| 52 Week High | $42.39 | $6.50 |
Technical Indicators
Market Signals| Indicator | RAPT | LEO |
|---|---|---|
| Relative Strength Index (RSI) | 56.26 | 42.33 |
| Support Level | $34.38 | $6.25 |
| Resistance Level | $36.92 | $6.30 |
| Average True Range (ATR) | 2.56 | 0.05 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 50.37 | 6.67 |
Price Performance
Historical ComparisonAbout RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
About LEO BNY Mellon Strategic Municipals Inc.
BNY Mellon Strategic Municipals, Inc. is a diversified closed-end management investment company. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. Its products are Equity and Fixed Income Mutual Funds, Retail Money Market Funds, Government/Treasury Money Market Funds, Institutional Money Market Funds, and others. BNY Mellon and its affiliates, including BNYM Investment Adviser, INA and others involved in the management, sales, investment activities, business operations or distribution of the Fund, are engaged in businesses and have interests other than that of managing the Fund.